AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06700681 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Maintain spontaneous ventilation without intubation
Description: Patient maintains spontaneous ventilation without intubation.
Study NCT06339827 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Administration of the ASk Questions in GYnecologic Oncology (ASQ-GYO) Question Prompt List
Description: Participants are randomized and will receive the ASQ-GYO prompt list within 2 weeks prior to their new patient appointment with the gynecology oncology physician.
Study NCT00863538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPS-0373
Study NCT06700772 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mixing bone marrow aspirate concentrate from maxillary tuberosity with bovine bone
Description: open sinus lifting using bone marrow aspirate concentrate from maxillary tuberosity and mixing it with bovine bone .
Study NCT06700772 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mixing autogenous bone with bovine bone
Description: open sinus lifting using autogenous bone from retromolar area mixed with bovine bone
Study NCT06702293 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital psychotherapeutic intervention
Description: Mobile app comprising various psychobehavioural tools to educate, enhance self-efficacy and coping and promote wellness in dermatological patients.
Study NCT06702293 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy365
Description: Mobile application by the Health Promotion Board (HPB) Singapore which aims to encourage users to adopt a healthier lifestyle.
Study NCT06701799 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAF+ L-PRF 1 mm
Description: The extent of the depth of the recession will be reported on the anatomical papillae and, after adding 1 mm, 2 horizontal incisions of approximately 3 mm will be made at the base of the surgical papillae laterally to the recession.Two divergent releasing incisions will be made extending approximately 2-3 mm into the alveolar mucosa.The surgical papillae will be detached in partial thickness. A full thickness dissection will be performed from the bottom of the recession to expose approximately 3mm of the crest bone.A partial thickness dissection will be performed in the most apical portion of the flap until complete passivation of the flap is obtained. The L-PRF membrane 1 mm in thickness, will be positioned at the level of the de-epithelialised anatomical papillae.The flap will be repositioned coronally suturing the anatomical papillae on the surgical ones, using a Non-Resorbable 5.0 Polyamide Suture.
Study NCT06701799 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAF+ L-PRF 2 mm
Description: The extent of the depth of the recession will be reported on the anatomical papillae and, after adding 1 mm, 2 horizontal incisions of approximately 3 mm will be made at the base of the surgical papillae laterally to the recession.Two divergent releasing incisions will be made extending approximately 2-3 mm into the alveolar mucosa.The surgical papillae will be detached in partial thickness. A full thickness dissection will be performed from the bottom of the recession to expose approximately 3mm of the crest bone.A partial thickness dissection will be performed in the most apical portion of the flap until complete passivation of the flap is obtained. The L-PRF membrane 2 mm in thickness, will be positioned at the level of the de-epithelialised anatomical papillae.The flap will be repositioned coronally suturing the anatomical papillae on the surgical ones, using a Non-Resorbable 5.0 Polyamide Suture.
Study NCT06702046 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous pulsed radiofrequency acupuncture
Description: For the TCPRF acupuncture group, we choose ST34 (Liangqiu), SP10 (Xuehai), GB34 (Yanglingquan), SP9 (Yinlingquan) around the affected knee. The TCPRF device is a wearable modality with innovative pulse radiofrequency technology aimed at alleviating symptomatic chronic pain, which revealed that UHF (500-kHz sine wave, 2-Hz frequency with a 25-ms pulse). It was attached to the electrode pad through magnetic attraction. A 500-KHz stimulus was delivered. The symmetric two-phase sine wave has a 2-Hz frequency witha 25-ms pulse width. The treatment has 15 min per time. Electrical stimulation is administered for 30 minutes each session, divided into two 15-minute phases. After the first 15 minutes, the treatment is paused and then restarted for an additional 15 minutes. The output peak current was 13.2 mA and the output peak voltage was 6.6 V at 500 Ω.
Study NCT06532695 — intervention group
Intervention type: OTHER
Intervention: No intervention will be provided.
Description: no intervention will be provided.
Study NCT06702046 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparison
Description: same protocol will be done on the same acupoints, but the machine will be turn off interiorly. Therefore, although the machine still has lights and a vibrating sensation, it will not release PRF waves.
Study NCT06702891 — intervention group
Intervention type: OTHER
Intervention: Detection of biological samples based on exosome sequencing, proteomics and single-cell RNA sequencing
Description: The researchers combined exosome sequencing, proteomics and single-cell RNA sequencing to explore the heterogeneity of cardia cancer, identify specific biomarkers and potential therapeutic targets for cardia cancer.
Study NCT06702826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab combined with SRS
Description: Eligible subjects were treated with stereotactic radiotherapy for brain metastases plus Cadonilimab followed by maintenance therapy with Cadonilimab alone
Study NCT06702397 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microscope
Description: The microscope provides a direct examination of the testicular parenchyma at 20-25x magnification.
Study NCT06702397 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical loupes
Description: Surgical loupes offer magnification of 3.5-5x.
Study NCT06703788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A fiixed combination of Chinese herbal medicine
Description: a fixed combination of Chinese herbal medicine with Ma-Xing-Gang-Shi-Tang (initiate at 2 grams, with increments of 0.5 grams every 2-4 weeks, up to a maximum dose of 4 grams once daily) and Coptis chinensis (initiate at 0.5 grams, with increments of 0.5 grams every 2-4 weeks, up to a maximum dose of 1 gram once daily), twice a day
Study NCT04777344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Treatment Specialist (TTS) intervention
Description: A trained Tobacco Treatment specialist (TTS) embedded in the multi-disciplinary CF care team will provide tobacco use counseling to smoking caregivers of children with CF.
Study NCT06703788 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Description: Laser acupuncture could be used based on medication therapy at following acupoints: CV9, ST25, SP15, ST28, ST40, and two auricular points (stomach and hunger points)
Study NCT06703580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric prilocaine 2% 40 mg
Description: this arm will include 50 patients who will receive intrathecal hyperbaric prilocaine 2% in a dose of 40 mg.
Study NCT06703580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyperbaric prilocaine 2% 50 mg
Description: comparison of 3 different doses of prilocaine
Study NCT06703580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyperbaric prilocaine 2% 60 mg
Description: this study compare 3 different doses of prilocaine
Study NCT06702514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: After their treatment, both groups will be given a daily exercise program (15 minutes of range of motion, 15 minutes of strengthening exercises) once a day, accompanied by a physiotherapist.
Study NCT06702514 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: After their treatment, both groups will be given a daily exercise program (15 minutes of range of motion, 15 minutes of strengthening exercises) once a day, accompanied by a physiotherapist.
Study NCT06702514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paraffin
Description: It was planned to apply paraffin treatment to both hands for 20 minutes, five times a week for 4 weeks, using one session per day for a total of 20 sessions.
Study NCT06702514 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paraffin
Description: It was planned to apply paraffin treatment to both hands for 20 minutes, five times a week for 4 weeks, using one session per day for a total of 20 sessions.
Study NCT06702514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balneotherapy
Description: The balneotherapy group will receive 20 minutes of paraffin and 20 minutes of balneotherapy on both hands, five times a week for 4 weeks, one session per day for a total of 20 sessions. The spa treatment will be given in the form of a 20-minute full body bath in the pool in each session. The spa water temperature will be 38-40 degrees Celsius.
Study NCT06703515 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Awake transnasal laser-assisted surgery (TNLS)
Description: For TNLS, patients are admitted to the day center on the same morning or afternoon of the surgery with fasting prior 6 hours. After local anesthesia application, a 445nm blue laser is introduced via a working channel of bronchoscope and laser ablation of vocal cord cyst is performed. During the operation, patient will receive continuous SpO2 monitoring with regular blood pressure monitoring. After the procedure, patients are kept nil-by-mouth for 2 hours until anesthesia wears off, meanwhile with close observation in day ward with continuous SpO2 monitor for 1 hour. Patients will be discharged on the same day of the procedure, with voice rest for 3 days.
Study NCT06703515 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microlaryngeal surgery (MLS)
Description: For traditional MLS under general anesthesia, after general anesthesia and intubation with microlaryngeal tube, the patient would be positioned on head-ring support for better alignment and access to glottis. A laryngoscope will be inserted transorally under direct vision and suspended. Vocal cord cysts are visualized with microscope, and removed with microsurgery instruments with microflap technique and sent for routine section. After the surgery, the patient is kept nil-by-mouth until fully awake, and is discharged on same day or the next day depending on the post- operative recovery. Patient will be discharged with voice rest for 3 days.
Study NCT06702709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument Assisted Soft Tissue Mobilization
Description: The IASTM method will be applied bilaterally to each target muscle, duration 25 minutes. During treatment, three repetitions are performed on each target muscle, with each repetition lasting 50 seconds. The IASTM technique will be applied at a 60-degree angle. The application sequence follows a specific pattern: For the first 10 seconds, light pressure will be applied during the sweeping stroke, and for the next 20 seconds, moderate pressure will apply during the fanning and brushing strokes. Finally, 10 seconds of deep pressure will administer utilizing oblique sweeping strokes. To help the tissues relax, the treatment will finish with mild sweeping and broad strokes on the hamstring region for 10 seconds
Study NCT06702709 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurodevelopmental Therapy
Description: The neurodevelopment therapy for spastic diplegic cerebral palsy includes tone-inhibitory postures. This study will use five-tone inhibitory postures that will be appropriate for the reduction of muscle tone, elongation of lower extremities muscles, and improve gross motor function by enhancing balance and stability. The following posture will be repeated 3 times on the bilateral lower limb in one session and maintained for 50 seconds with 60 seconds rest between each posture. The total duration of NDT will be 25 minutes.
Study NCT06519266 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PHP
Description: Patients will be treated with 2 cycles of PHP (CHEMOSAT® Hepatic Delivery System for Melphalan) six weeks apart
Study NCT06519266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI1/NIVO3
Description: Patients will be treated with 2 cycles of i.v. ipilimumab 1mg/kg and nivolumab 3mg/kg q3w, followed by continued i.v. nivolumab 480mg q4w up to 1 year.
Study NCT06519266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IPI3/NIVO1
Description: Patients will be treated with 4 cycles of intravenous (i.v.) infusion with ipilimumab 3mg/kg and nivolumab 1mg/kg q3w followed by continued i.v. nivolumab 480mg q4w up to 1 year.
Study NCT06253585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Algorithm Alarm- Crystalloids
Description: The study uses an algorithm implemented within the Electronic Health Record (EHR). This algorithm identifies patients who belong to a sepsis subphenotype known as Group D, in whom published data has shown a mortality benefit from balanced crystalloids compared to normal saline.~The intervention is an EHR alert when clinicians order normal saline on Group D patients randomized to intervention. In the intervention arm, if a clinician orders normal saline in a patient classified as Group D, there will be an EHR alert to change the order to balanced crystalloids (i.e., Lactated Ringer or Plasma-Lyte solution).
Study NCT06253585 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Enrolled patients who are classified to Group D by the algorithm will be randomized within the electronic health record to usual care. In the usual care arm, the clinicians will not have any feedback from the algorithm and will not know the Group classification of their patient or the recommended fluid type.
Study NCT06290622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab, INCAGN02385, INCAGN02390
Description: Treatment:~Retifanlimab -infused over 60 minutes for C1D1 followed by a 60-minute observation period. If no infusion related reactions are observed infusion may be reduced to 30 minutes and no further observation period is needed for future cycles. If there is a reaction continue with 60 minute infusion and observation period for following cycle. Retifanlimab should always be administered first.~INCAGN02385 and INCAGN02390 -individually administered over 30 minutes one after another. For first infusions of retifanlimab, INCAGN02385 and INCAGN02390, a 4 hour observation period is necessary after completion of all infusion. If no infusion related reactions are observed, for subsequent infusions no further observation period is needed for future cycles.
Study NCT05237687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Patients will be randomly assigned to sirolimus or standard of care
Study NCT05529992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velaglucerase Alfa
Description: VPRIV intravenous infusion every other week for 60 minutes.
Study NCT05645562 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education program
Description: 1. Types of pain (peripherical and central pain)~2. Pain as information.~3. Benign and harmful pain~4. Psychological factors and pain in sport (Injuries, catastrophizing and pain)
Study NCT05645562 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-care education program
Description: 1. The importance of resting~2. Nutritional habits~3. Recovery techniques for athletes~4. Principles of stretching, strengthening and endurance training
Study NCT06128135 — intervention group
Intervention type: OTHER
Intervention: Technology acceptance questionnaire for prostheses users.
Description: One questionnaire, which is for prosthesis users, where will be 15 questions to identify what kind of activities the person uses the prosthesis, how much is the use time and what is the main problem with the device.
Study NCT06128135 — intervention group
Intervention type: OTHER
Intervention: Technology acceptance questionnaire for relatives of prostheses users.
Description: One questionnaire, where there will be between 8 questions to analyze which device characteristics, they think cause major discomfort during the use and could be improved.
Study NCT06128135 — intervention group
Intervention type: OTHER
Intervention: Technology acceptance questionnaire for therapists
Description: One questionnaire, where there will be between 9 questions to analyze which device characteristics, they think cause major discomfort during the use and could be improved.
Study NCT05828667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incorporation of CT and/or c-MRI derived myocardial scar with 3D electroanatomical mapping (EAM).
Description: CT and/or c-MRI derived myocardial scar will be merged with 3D electroanatomical mapping (EAM) prior to the ablation to allow for readily localization and characterization of VT substrates and potential re-entry circuits to be ablated. This is done with the intent to limit the repeated number of inductions and prolonged point-by-point voltage mapping that often result in hemodynamic instability.
Study NCT05565105 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: Hyper-fractioned TBI is administered by a linear accelerator at a dose rate of \< 15 cGy/minute.
Study NCT05565105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Thiotepa: 5 mg/kg/day IV over approximately 4 hours daily x 2 (Day -5 and Day -4).
Study NCT05565105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide: 60 mg/kg/day x 2 or Fludarabine 25 mg/m\^2 x 5 if cyclophosphamide is contraindicated
Study NCT05565105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan: 0.8 mg/kg every 6 hours x 10 or 12 doses (depending on disease) with dose modified according to pharmacokinetics
Study NCT05565105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan: 70 mg/m\^2/day x 2
Study NCT05565105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine: 25 mg/m\^2/day x 5
Study NCT05489380 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: AccuMeasure
Description: intracolonoscopy measurement of polyps using a laser-based device
Study NCT05917938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0194-0499
Description: NNC0194-0499 will be administered subcutaneously in a skinfold in the thigh in the form of a solution for injection.
Study NCT04928794 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Erector Spinae Plane Block
Description: Regional anesthesia with injected local anesthetic solution, placed in space underlying erector spinae muscles
Study NCT04928794 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Paravertebral Block
Description: Regional anesthesia with injected local anesthetic solution, placed in space adjacent to vertebrae
Study NCT06087198 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: T-TAS 01 HD Assay
Description: Disposable flow chamber microchip containing thrombogenic path to facilitate thrombus formation and occlusion
Study NCT05769153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-14034 SR implant lower dose
Description: AR-14034 SR administered as an intravitreal implant
Study NCT05769153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection
Description: Aflibercept administered as a 2 milligram (mg) intravitreal injection
Study NCT05769153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept Injection
Description: Aflibercept administered as a 2 milligram (mg) intravitreal injection
Study NCT05769153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sham procedure
Description: Needleless syringe used to simulate an intravitreal injection
Study NCT05769153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sham procedure
Description: Needleless syringe used to simulate an intravitreal injection
Study NCT05769153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-14034 SR implant higher dose
Description: AR-14034 SR administered as an intravitreal implant
Study NCT05437146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: puppet
Description: pain and fear during blood collection
Study NCT04943913 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes (TIL)
Description: Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
Study NCT06271941 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid Argon Plasma Coagulation (h-APC)
Description: The hybrid argon plasma coagulation (h-APC) combines an ablation technique (APC) with the option for submucosal saline injection using a high-pressure water jet. The technique allows for the lifting of dysplastic epithelium, creating a cushion under the mucosa to facilitate the ablation of larger areas more thoroughly and with higher energy settings, while posing a low risk for side effects or complications.
Study NCT06271941 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Snare tip soft coagulation (STSC)
Description: The Snare tip soft coagulation (STSC) involves using a snare to remove polyps, while simultaneously applying soft coagulation to the surrounding tissue using a specialized tip on the snare.
Study NCT04476654 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: YouTube Video Arm
Description: Participants (n=25) will watch a 20 minute YouTube video that will describe the genetic counseling and testing process and risk/benefit information in a culturally relevant format. Participants will complete pre and post assessments. After the session, participants interested in pursuing genetic counseling and testing services will be referred to a patient navigator who will navigate participants to identified no cost or low cost services.